AXRX — Amexdrug Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Amexdrug, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2008 December 31st	2009 December 31st	2010 December 31st	2011 December 31st	2012 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5.69	9.77	11.5	12.4	9.15
Cost of Revenue
Gross Profit	0.455	0.722	0.963	0.996	1.01
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	5.66	9.71	11.2	12.2	8.95
Operating Profit	0.034	0.055	0.29	0.217	0.196
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	0.018	0.027	0.266	0.187	0.16
Provision for Income Taxes
Net Income After Taxes	0.013	0.018	0.189	0.101	0.082
Net Income Before Extraordinary Items
Net Income	0.013	0.018	0.189	0.101	0.082
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	0.013	0.018	0.189	0.101	0.082
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0	0	0.001	0.001	0
Dividends per Share